GILD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24,975.00 |
| 52 Week High | US$28,651.00 |
| 52 Week Low | US$15,000.00 |
| Beta | 0.19 |
| 11 Month Change | -5.13% |
| 3 Month Change | 0.81% |
| 1 Year Change | 39.09% |
| 33 Year Change | 554.65% |
| 5 Year Change | 1,906.02% |
| Change since IPO | 3,507.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| GILD | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | -5.8% | 0% | 0% |
| 1Y | 39.1% | 0% | 0% |
Return vs Industry: GILD exceeded the AR Biotechs industry which returned 8.9% over the past year.
Return vs Market: GILD underperformed the AR Market which returned 134.6% over the past year.
Price Volatility
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: GILD has not had significant price volatility in the past 3 months compared to the AR market.
Volatility Over Time: GILD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILD fundamental statistics | |
|---|---|
| Market cap | AR$110.90t |
| Earnings (TTM) | AR$126.50b |
| Revenue (TTM) | AR$28.41t |
887.8x
P/E Ratio4.0x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILD income statement (TTM) | |
|---|---|
| Revenue | US$28.30b |
| Cost of Revenue | US$6.28b |
| Gross Profit | US$22.02b |
| Other Expenses | US$21.89b |
| Earnings | US$126.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 77.80% |
| Net Profit Margin | 0.45% |
| Debt/Equity Ratio | 126.4% |
How did GILD perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield3,027%
Payout RatioDoes GILD pay a reliable dividends?
See GILD dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Dec 13 2024 |
| Dividend Pay Date | Dec 30 2024 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 38 days |
Does GILD pay a reliable dividends?
See GILD dividend history and benchmarks